

Department of Planning and Budget 2024 Session Fiscal Impact Statement

1. **Bill Number:** HB342S1

House of Origin Introduced Substitute Engrossed
Second House In Committee Substitute Enrolled

2. **Patron:** Hope

3. **Committee:** Finance and Appropriations

4. **Title:** Naloxone or other opioid antagonists; possession and administration by state agencies.

5. **Summary:** The bill provides that the Department of Health shall convene a work group of relevant stakeholders to study the implementation of a strategic plan for employees of each state agency to possess naloxone or other opioid antagonists used for overdose reversal. In its study, the work group shall identify the state agencies that should be prioritized for distribution of naloxone or other opioid antagonists, develop an implementation plan to distribute the naloxone or other opioid antagonists to such prioritized state agencies, and then distribute naloxone or other opioid antagonists to other state agencies in phases based on the impact, effectiveness, need, and results of such an initial prioritized distribution. The work group shall report its findings and statewide strategic plan to the Governor and the Chairmen of the House Committee on Health and Human Services and the Senate Committee on Education and Health by November 1, 2024.

6. **Budget Amendment Necessary:** No

7. **Fiscal Impact Estimates:** None

8. **Fiscal Implications:** The bill directs the Virginia Department of Health (VDH) to convene a work group and develop an implementation plan for Naloxone distribution. VDH can absorb any increase in workload related to this provision.

9. **Specific Agency or Political Subdivisions Affected:** Department of General Services, Department of Health, all state agencies and employees

10. **Technical Amendment Necessary:** No

11. **Other Comments:** None